GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » Capex-to-Operating-Cash-Flow

SenzaGen AB (OSTO:SENZA) Capex-to-Operating-Cash-Flow : 0.20 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is SenzaGen AB Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

SenzaGen AB's Capital Expenditure for the three months ended in Sep. 2024 was kr-0.50 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was kr2.52 Mil.

Hence, SenzaGen AB's Capex-to-Operating-Cash-Flow for the three months ended in Sep. 2024 was 0.20.


SenzaGen AB Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for SenzaGen AB's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SenzaGen AB Capex-to-Operating-Cash-Flow Chart

SenzaGen AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

SenzaGen AB Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.12 - - 0.20

Competitive Comparison of SenzaGen AB's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, SenzaGen AB's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SenzaGen AB's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where SenzaGen AB's Capex-to-Operating-Cash-Flow falls into.



SenzaGen AB Capex-to-Operating-Cash-Flow Calculation

SenzaGen AB's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.808) / -16.453
=N/A

SenzaGen AB's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.5) / 2.518
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SenzaGen AB  (OSTO:SENZA) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


SenzaGen AB Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of SenzaGen AB's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


SenzaGen AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Building 401, Lund, SWE, 223 81
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

SenzaGen AB Headlines

No Headlines